These two Fate series are a great way to pass the time until an official release date drops for the first season of ...

Sage Therapeutics has a unique approach to targeting GABA, which allows it to target CNS disorders. Read why I think SAGE ...

The firm will evaluate its CLDN6- and CD3 T-cell-engaging bispecific antibody in advanced or metastatic ovarian, endometrial, and testicular cancers.

Bristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer’s-related psychosis during the ...

Research presented at SABCS 2024 provided new insights that may influence the management of early and advanced breast cancer.

CTIM-76 Phase 1 trial focused on CLDN6-positive gynecologic and testicular cancers Trial marks key milestone in driving pipeline progress PHILADELPHIA, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Context ...

Context Therapeutics (CNTX) announced the appointment of Andy Pasternak as Chairman of its Board of Directors, succeeding Richard Berman, who ...

Piper Sandler reaffirmed its Overweight rating on shares of Context Therapeutics (NASDAQ:CNTX) with a steady price target of $4.50. The firm's stance follows recent data... H.C. Wainwright has ...

PHILADELPHIA, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the“Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors ...

Shares of Context Therapeutics Inc. (NASDAQ:CNTX – Get Free Report) have earned a consensus rating of “Buy” from the seven brokerages that are covering the stock, MarketBeat.com reports. Six research ...

Travere Therapeutics, Inc. ( NASDAQ ... over the past year with earnings forecast to grow by 15% annually. In this context, identifying high growth tech stocks that align with these robust market ...